Sunitinib in metastatic thymic carcinomas: Laboratory findings and initial clinical experience

BACKGROUND: Thymic carcinoma (TC) is a rare aggressive tumour. Median survival with current treatments is only 2 years. Sunitinib is a multi-targeted tyrosine kinase inhibitor that has shown benefit in various other cancers. METHODS: Laboratory analyses of snap-frozen tumour tissues were performed t...

Fuld beskrivelse

Na minha lista:

Bibliografiske detaljer
Main Authors:	Ströbel, P, Bargou, R, Wolff, A, Spitzer, D, Manegold, C, Dimitrakopoulou-Strauss, A, Strauss, L, Sauer, C, Mayer, F, Hohenberger, P, Marx, A
Format:	Artigo
Sprog:	Inglês
Udgivet:	Nature Publishing Group 2010
Fag:	Translational Therapeutics
Online adgang:	https://ncbi.nlm.nih.gov/pmc/articles/PMC2906735/ https://ncbi.nlm.nih.gov/pubmed/20571495 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605740
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

Sunitinib in metastatic thymic carcinomas: Laboratory findings and initial clinical experience

Lignende værker